Background and Objectives: Therapeutic interventions to improve the efficacy of whole-body cooling for hypoxic-ischemic encephalopathy (HIE) are desirable. Topiramate has been effective in reducing brain damage in experimental studies. However, in the clinical setting information is limited to a small number of feasibility trials. We launched a randomized controlled double-blinded topiramate/placebo multicenter trial with the primary objective being to reduce the antiepileptic activity in cooled neonates with HIE and assess if brain damage would be reduced as a consequence. Study Design: Neonates were randomly assigned to topiramate or placebo at the initiation of hypothermia. Topiramate was administered via a nasogastric tube. Brain electric activity was continuously monitored. Topiramate pharmacokinetics, energy-related and Krebs’ cycle intermediates, and lipid peroxidation biomarkers were determined using liquid chromatography-mass spectrometry and MRI for assessing brain damage. Results: Out of 180 eligible patients 110 were randomized, 57 (51.8%) to topiramate and 53 (48.2%) to placebo. No differences in the perinatal or postnatal variables were found. The topiramate group exhibited less seizure burden in the first 24 h of hypothermia (topiramate, n = 14 [25.9%] vs. placebo, n = 22 [42%]); needed less additional medication, and had lower mortality (topiramate, n = 5 [9.2%] vs. placebo, n = 10 [19.2%]); however, these results did not achieve statistical significance. Topiramate achieved a therapeutic range in 37.5 and 75.5% of the patients at 24 and 48 h, respectively. A significant association between serum topiramate levels and seizure activity (p < 0.016) was established. No differences for oxidative stress, energy-related metabolites, or MRI were found. Conclusions: Topiramate reduced seizures in patients achieving therapeutic levels in the first hours after treatment initiation; however, they represented only a part of the study population. Our results warrant further studies with higher loading and maintenance dosing of topiramate.

1.
Natarajan
G
,
Laptook
A
,
Shankaran
S
.
Therapeutic hypothermia: how can we optimized this therapy to further improve outcomes?
Clin Perinatol
.
2018
Jun
;
45
(
2
):
241
55
.
[PubMed]
0095-5108
2.
Torres-Cuevas
I
,
Parra-Llorca
A
,
Sánchez-Illana
A
,
Nuñez-Ramiro
A
,
Kuligowski
J
,
Cháfer-Pericás
C
, et al
Oxygen and oxidative stress in the perinatal period
.
Redox Biol
.
2017
Aug
;
12
:
674
81
.
[PubMed]
2213-2317
3.
Johnston
MV
,
Fatemi
A
,
Wilson
MA
,
Northington
F
.
Treatment advances in neonatal neuroprotection and neurointensive care
.
Lancet Neurol
.
2011
Apr
;
10
(
4
):
372
82
.
[PubMed]
1474-4422
4.
Martinello
K
,
Hart
AR
,
Yap
S
,
Mitra
S
,
Robertson
NJ
.
Management and investigation of neonatal encephalopathy: 2017 update
.
Arch Dis Child Fetal Neonatal Ed
.
2017
Jul
;
102
(
4
):
F346
58
.
[PubMed]
1359-2998
5.
Wassink
G
,
Gunn
ER
,
Drury
PP
,
Bennet
L
,
Gunn
AJ
.
The mechanisms and treatment of asphyxial encephalopathy
.
Front Neurosci
.
2014
Feb
;
8
:
40
.
[PubMed]
1662-4548
6.
Murray
DM
,
Boylan
GB
,
Ali
I
,
Ryan
CA
,
Murphy
BP
,
Connolly
S
.
Defining the gap between electrographic seizure burden, clinical expression and staff recognition of neonatal seizures
.
Arch Dis Child Fetal Neonatal Ed
.
2008
May
;
93
(
3
):
F187
91
.
[PubMed]
1359-2998
7.
Shah
DK
,
Wusthoff
CJ
,
Clarke
P
,
Wyatt
JS
,
Ramaiah
SM
,
Dias
RJ
, et al
Electrographic seizures are associated with brain injury in newborns undergoing therapeutic hypothermia
.
Arch Dis Child Fetal Neonatal Ed
.
2014
May
;
99
(
3
):
F219
24
.
[PubMed]
1359-2998
8.
Dixon
BJ
,
Reis
C
,
Ho
WM
,
Tang
J
,
Zhang
JH
.
Neuroprotective strategies after neonatal hypoxia ischemic encephalopathy
.
Int J Mol Sci
.
2015
Sep
;
16
(
9
):
22368
401
.
[PubMed]
1661-6596
9.
Glass
HC
,
Poulin
C
,
Shevell
MI
.
Topiramate for the treatment of neonatal seizures
.
Pediatr Neurol
.
2011
Jun
;
44
(
6
):
439
42
.
[PubMed]
0887-8994
10.
Filippi
L
,
Poggi
C
,
la Marca
G
,
Furlanetto
S
,
Fiorini
P
,
Cavallaro
G
, et al
Oral topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia: a safety study
.
J Pediatr
.
2010
Sep
;
157
(
3
):
361
6
.
[PubMed]
0022-3476
11.
Filippi
L
,
Fiorini
P
,
Catarzi
S
, et al
Safety and efficacy of topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia (NeoNATI): a feasibility study
.
J Matern Fetal Neonatal Med
.
2017
;
28
:
1
8
.
[PubMed]
1476-7058
12.
Shankaran
S
,
Laptook
AR
,
Ehrenkranz
RA
,
Tyson
JE
,
McDonald
SA
,
Donovan
EF
, et al;
National Institute of Child Health and Human Development Neonatal Research Network
.
Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy
.
N Engl J Med
.
2005
Oct
;
353
(
15
):
1574
84
.
[PubMed]
0028-4793
13.
Hellström-Westas
L
,
Rosén
I
,
de Vries
LS
,
Greisen
G
.
Amplitude-integrated EEG classification and interpretation in preterm and term infants
.
Neoreviews
.
2006
;
7
(
2
):
e76
87
. 1526-9906
14.
Hellström-Westas
L
.
Monitoring brain function with aEEG in term asphyxiated infants before and during cooling
.
Acta Paediatr
.
2013
Jul
;
102
(
7
):
678
9
.
[PubMed]
0803-5253
15.
Vento
M
,
de Vries
LS
,
Alberola
A
,
Blennow
M
,
Steggerda
S
,
Greisen
G
, et al
Approach to seizures in the neonatal period: a European perspective
.
Acta Paediatr
.
2010
Apr
;
99
(
4
):
497
501
.
[PubMed]
0803-5253
16.
Rutherford
M
,
Ramenghi
LA
,
Edwards
AD
,
Brocklehurst
P
,
Halliday
H
,
Levene
M
, et al
Assessment of brain tissue injury after moderate hypothermia in neonates with hypoxic-ischaemic encephalopathy: a nested substudy of a randomised controlled trial
.
Lancet Neurol
.
2010
Jan
;
9
(
1
):
39
45
.
[PubMed]
1474-4422
17.
Sánchez-Illana
Á
,
Núñez-Ramiro
A
,
Cernada
M
,
Parra-Llorca
A
,
Valverde
E
,
Blanco
D
, et al;
HYPOTOP Study Group
.
Evolution of Energy Related Metabolites in Plasma from Newborns with Hypoxic-Ischemic Encephalopathy during Hypothermia Treatment
.
Sci Rep
.
2017
Dec
;
7
(
1
):
17039
.
[PubMed]
2045-2322
18.
Kuligowski
J
,
Escobar
J
,
Quintás
G
,
Lliso
I
,
Torres-Cuevas
I
,
Nuñez
A
, et al
Analysis of lipid peroxidation biomarkers in extremely low gestational age neonate urines by UPLC-MS/MS
.
Anal Bioanal Chem
.
2014
Jul
;
406
(
18
):
4345
56
.
[PubMed]
1618-2642
19.
Patsalos
PN
,
Berry
DJ
,
Bourgeois
BF
,
Cloyd
JC
,
Glauser
TA
,
Johannessen
SI
, et al
Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies
.
Epilepsia
.
2008
Jul
;
49
(
7
):
1239
76
.
[PubMed]
0013-9580
20.
Rakhade
SN
,
Zhou
C
,
Aujla
PK
,
Fishman
R
,
Sucher
NJ
,
Jensen
FE
. Early alterations of AMPA receptors mediate synaptic potentiation induced by neonatal seizures. J Neurosci
2008
;28:7979e90.
21.
El-Dib
M
,
Soul
JS
.
The use of phenobarbital and other anti-seizure drugs in newborns
.
Semin Fetal Neonatal Med
.
2017
Oct
;
22
(
5
):
321
7
.
[PubMed]
1744-165X
22.
Filippi
L
,
la Marca
G
,
Fiorini
P
,
Poggi
C
,
Cavallaro
G
,
Malvagia
S
, et al
Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic ischemic encephalopathy
.
Epilepsia
.
2009
Nov
;
50
(
11
):
2355
61
.
[PubMed]
0013-9580
23.
Colbourne
F
,
Grooms
SY
,
Zukin
RS
,
Buchan
AM
,
Bennett
MV
.
Hypothermia rescues hippocampal CA1 neurons and attenuates down-regulation of the AMPA receptor GluR2 subunit after forebrain ischemia
.
Proc Natl Acad Sci USA
.
2003
Mar
;
100
(
5
):
2906
10
.
[PubMed]
0027-8424
24.
Saugstad
OD
.
Is lactate a reliable indicator of tissue hypoxia in the neonatal period?
Acta Paediatr
.
2002
;
91
(
1
):
17
9
.
[PubMed]
0803-5253
25.
Takenouchi
T
,
Sugiura
Y
,
Morikawa
T
,
Nakanishi
T
,
Nagahata
Y
,
Sugioka
T
, et al
Therapeutic hypothermia achieves neuroprotection via a decrease in acetylcholine with a concurrent increase in carnitine in the neonatal hypoxia-ischemia
.
J Cereb Blood Flow Metab
.
2015
May
;
35
(
5
):
794
805
.
[PubMed]
0271-678X
26.
Chouchani
ET
,
Pell
VR
,
Gaude
E
,
Aksentijević
D
,
Sundier
SY
,
Robb
EL
, et al
Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS
.
Nature
.
2014
Nov
;
515
(
7527
):
431
5
.
[PubMed]
0028-0836
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.